vaccin
develop
greater
number
pathogen
ever
challeng
except
level
activ
invest
select
resourc
promis
approach
signific
impact
public
health
product
develop
vaccin
advisori
committe
pdvac
establish
provid
strateg
advic
recommend
vaccin
clinic
develop
could
signific
impact
public
health
low
middl
incom
countri
septemb
pdvac
conven
second
time
committe
review
vaccin
develop
diseas
area
report
summaris
key
recommend
consult
human
pathogen
pdvac
remit
consid
acceler
vaccin
candid
phase
stage
clinic
evalu
earlier
diseas
area
substanti
diseas
burden
low
middl
incom
countri
lmic
vaccin
current
exist
ongo
product
develop
activ
may
benefit
guidanc
one
potenti
key
output
pdvac
review
recommend
gener
guidanc
document
describ
prefer
product
characterist
ppc
vaccin
particular
pathogen
ppc
document
describ
prefer
vaccin
use
lmic
particular
indic
target
group
featur
desir
clinic
data
relat
safeti
efficaci
intend
provid
earli
guidanc
develop
least
year
vaccin
approv
ensur
licens
data
avail
enabl
decisionmak
use
vaccin
popul
need
conven
second
pdvac
meet
geneva
septemb
involv
subject
matter
expert
vaccin
industri
academia
public
privat
partnership
month
sinc
first
meet
vaccin
research
develop
landscap
shift
significantli
renew
focu
prepared
emerg
infecti
diseas
wake
ebola
emerg
reason
agenda
includ
overview
unpreced
process
timelin
interim
efficaci
data
ebola
vaccin
report
ongo
phase
iii
studi
well
target
product
profil
finalis
public
avail
addit
committe
inform
effort
establish
blueprint
emerg
r
prepared
research
respons
middl
eastern
respiratori
syndromecoronaviru
merscov
review
ongo
case
studi
emerg
pathogen
auspic
recent
form
initi
prior
meet
committe
review
pathogenspecif
landscap
analys
outlin
unmet
public
health
need
current
vaccin
develop
statu
product
develop
challeng
document
includ
special
vaccin
supplement
pipelin
vaccin
pdvac
websit
pathogen
subject
matter
expert
describ
statu
vaccin
develop
present
committe
pdvac
remit
consid
vaccin
like
clinic
proof
concept
data
within
next
year
identifi
area
clear
role
play
increas
likelihood
vaccin
use
reduc
diseas
burden
lmic
pdvac
vaccin
prioritis
committe
rather
committe
assess
vaccin
pipelin
determin
activ
guidanc
may
best
acceler
vaccin
diseas
preval
lmic
report
summaris
conclus
recommend
meet
intend
depth
summari
product
develop
statu
pathogen
pleas
refer
individu
landscap
analys
meet
present
websit
also
mani
pathogen
discuss
pdvac
remain
import
prioriti
vaccin
research
develop
respiratori
syncyti
viru
rsv
group
b
streptococcu
gb
pathogen
major
unmet
public
health
need
particularli
neonat
infant
lmic
pathogen
matern
immunis
could
reduc
risk
neonat
infect
death
passiv
placent
transfer
matern
antibodi
although
new
vaccin
condit
may
establish
preced
matern
immunis
initi
indic
exist
vaccin
influenza
tetanu
recommend
immunis
pregnant
women
inde
case
influenza
highlight
pregnant
women
highest
prioriti
target
group
vaccin
rsv
highlight
inaugur
pdvac
meet
pathogen
signific
clinic
pipelin
activ
likelihood
candid
emerg
licensur
near
term
novavax
rsv
fprotein
base
nanoparticl
vaccin
remain
advanc
candid
phase
iii
studi
pregnant
women
start
end
follow
demonstr
phase
ii
studi
palivizumabcompet
antibodi
rsv
neutralis
antibodi
elicit
transfer
infant
addit
recent
preliminari
data
elderli
demonstr
efficaci
phase
iii
trial
initi
target
popul
gsk
j
j
also
rsv
f
vaccin
clinic
develop
target
pregnant
women
medimmun
develop
rsv
f
vaccin
use
elderli
number
group
rsv
f
vaccin
preclin
develop
includ
niaid
rsv
subunit
vaccin
contain
sh
protein
immunovax
also
current
evalu
adult
number
live
vaccin
clinic
develop
activ
immunis
infant
young
children
includ
nativ
rsv
candid
nonessenti
gene
delet
adenoviru
vector
contain
rsv
f
gene
passiv
prophylaxi
longhalf
life
monoclon
antibodi
develop
medimmun
current
evalu
doseescalationpharmacokinet
trial
healthi
preterm
infant
follow
pdvac
meet
conven
consult
provid
guidanc
clinic
endpoint
develop
pathway
matern
paediatr
rsv
vaccin
candid
focu
consider
lmic
addit
path
nation
institut
biolog
standard
control
nibsc
collabor
develop
refer
reagent
view
establish
intern
standard
effort
develop
ppc
well
propos
roadmap
rsv
vaccin
underway
discuss
consult
given
signific
progress
rsv
vaccin
develop
specif
rsv
updat
provid
inform
strateg
advisori
group
expert
sage
april
gb
signific
caus
infant
mortal
particularli
neonat
period
death
occur
lmic
treatment
intrapartum
antibiot
prophylaxi
iap
gener
use
high
level
matern
anticapsular
polysaccharid
cp
igg
correl
reduc
neonat
diseas
risk
vaccin
circul
serotyp
may
protect
diseas
two
larg
pharmaceut
compani
current
engag
gb
vaccin
develop
glaxo
smithklin
consid
phase
iii
studi
design
candid
propos
approach
identifi
specif
anticp
igg
threshold
clinic
correl
protect
base
estim
diseas
risk
reduct
rather
convent
clinic
diseas
endpoint
mind
pdvac
recommend
develop
guidanc
test
develop
pathway
gb
vaccin
includ
consensu
strateg
goal
clinic
trial
design
consider
develop
ppc
key
develop
consider
includ
ethic
issu
conduct
vaccin
efficaci
studi
popul
high
gb
incid
part
africa
iap
standard
care
global
nearli
billion
case
diarrhoeal
diseas
everi
year
mani
acut
chronic
effect
global
enter
multicent
studi
gem
larg
multicountri
casecontrol
studi
aetiolog
case
moderatetosever
diarrhoea
molecular
reanalysi
randomli
select
sampl
collect
studi
use
qpcr
rather
cultur
confirm
etec
shigella
two
signific
pathogen
caus
moderatetosever
diarrhoea
among
children
year
old
africa
south
asia
account
around
diarrhoea
episod
month
old
addit
diarrhoeal
diseas
etec
shigella
infect
result
estim
million
children
moder
sever
stunt
due
malnutrit
account
addit
death
annual
kill
etvax
live
attenu
whole
vaccin
approach
combin
adjuv
doubl
mutant
heat
labil
toxin
dmlt
advanc
etec
vaccin
candid
sever
shigella
vaccin
candid
base
live
attenu
subunit
approach
also
clinic
studi
trial
vaccin
face
similar
challeng
etec
respect
requir
multival
approach
assay
standardis
identifi
correl
protect
well
defin
appropri
clinic
trial
endpoint
clinic
trial
design
field
trial
endem
area
addit
uncertain
whether
standalon
etec
shigella
vaccin
would
implement
whether
develop
prioritis
develop
combin
etecshigella
vaccin
intend
expand
current
capac
support
consensu
build
guidanc
decisionmak
area
readi
phase
iii
studi
recent
publish
male
studi
document
occurr
communityassoci
nonsever
diarrhoeal
episod
site
differ
countri
identifi
noroviru
specif
gii
strain
highest
attribut
fraction
noroviru
caus
estim
death
per
year
global
takeda
lead
vaccin
candid
clinic
proof
concept
demonstr
human
challeng
model
vaccin
enter
phase
iib
clinic
studi
adult
paediatr
immin
bival
candid
vaccin
base
combin
vlp
design
offer
crossprotect
human
genotyp
howev
ongo
expand
surveil
need
monitor
circul
strain
replac
ensur
candid
abl
protect
emerg
genotyp
well
better
document
diseas
burden
mind
pdvac
advis
explor
possibl
incorpor
noroviru
surveil
within
rotaviru
surveil
network
gvap
framework
approv
world
health
assembl
achiev
decad
vaccin
vision
individu
commun
live
free
vaccin
prevent
diseas
within
framework
specif
object
research
develop
indic
relat
progress
toward
vaccin
hiv
malaria
tuberculosi
univers
vaccin
influenza
accord
gvap
monitor
evalu
framework
progress
toward
r
relat
object
conduct
everi
second
year
pdvac
scrutinis
progress
toward
r
indic
issu
recommend
gvap
assess
report
develop
effort
vaccin
stand
item
pdvac
review
four
hiv
vaccin
concept
test
six
efficaci
trial
last
year
one
studi
evalu
heterolog
prime
boost
regimen
demonstr
modest
level
efficaci
partnership
establish
wake
trial
optimis
alvacprotein
heterolog
primeboost
approach
differ
adjuv
phase
iii
studi
new
regimen
underway
south
africa
agre
gonogo
decis
criteria
proceed
phase
iii
base
interim
data
expect
earli
final
efficaci
read
expect
earli
follow
year
follow
pdvac
commend
major
progress
toward
phase
trial
hiv
vaccin
acknowledg
novel
approach
hiv
field
advanc
vaccin
develop
pathogen
global
tb
strateg
goal
aim
reduct
tb
mortal
worldwid
reduct
tb
incid
compar
level
acknowledg
reduct
target
achiev
without
develop
novel
tool
tb
control
failur
tb
vaccin
show
efficaci
tb
vaccin
commun
refocus
earli
stage
translat
research
experiment
medicin
studi
evalu
divers
candid
portfolio
respect
antigen
deliveri
platform
acceler
evalu
reduc
cost
novel
clinic
studi
design
use
collect
clinic
proof
concept
data
target
high
incid
popul
recent
model
data
indic
target
vaccin
adolesc
adult
may
highest
earliest
public
health
impact
costeffect
consensu
emerg
develop
vaccin
prevent
pulmonari
tuberculosi
age
popul
signific
focu
pdvac
note
complex
polici
perspect
improv
bcg
vaccin
includ
issu
relat
nonspecif
benefici
effect
ascrib
bcg
vaccin
committe
encourag
work
develop
pathway
adolescentsadult
indic
note
basic
translat
research
remain
import
focu
progress
advanc
candid
rt
review
note
european
medicin
agenc
issu
posit
scientif
opinion
vaccin
juli
next
step
rt
explor
remain
interest
second
gener
malaria
vaccin
publish
malaria
vaccin
ppc
document
outlin
prefer
second
gener
malaria
vaccin
two
class
firstli
highli
effect
vaccin
reduc
morbid
mortal
secondli
vaccin
prevent
transmiss
purpos
enabl
malaria
elimin
progress
transmiss
block
vaccin
trial
mali
whole
parasit
vaccin
develop
highlight
includ
one
two
highest
prioriti
group
explor
progress
vaccin
design
prevent
pregnancyassoci
malaria
pathway
licensur
use
vaccin
yet
well
characteris
note
plasmodium
vivax
remain
neglect
vaccin
research
activ
despit
substanti
diseas
burden
due
malaria
parasit
especi
asia
note
control
human
malaria
infect
model
remain
import
approach
initi
screen
potenti
malaria
vaccin
candid
pdvac
consid
case
improv
season
influenza
vaccin
approach
optimis
current
avail
vaccin
improv
magnitud
qualiti
durat
protect
respons
potenti
offer
protect
one
influenza
season
howev
licensur
season
vaccin
base
mani
jurisdict
achiev
establish
hemagglutin
inhibit
hai
threshold
develop
improv
season
vaccin
may
repres
lower
hang
fruit
term
regulatori
accept
compar
timelin
truli
univers
influenza
vaccin
committe
advis
develop
strateg
public
health
goal
ppc
improv
season
influenza
vaccin
provid
guidanc
data
would
need
establish
improv
perform
vaccin
addit
conven
eighth
meet
develop
influenza
vaccin
induc
broadli
protect
longlast
immun
respons
august
four
dengu
serotyp
capabl
caus
full
spectrum
diseas
lifelong
homotyp
protect
confer
initi
infect
heterotyp
protect
serotyp
shortliv
second
infect
differ
serotyp
like
caus
sever
dengu
diseas
presum
antibodydepend
enhanc
ade
two
vaccin
candid
soon
begin
phase
trial
one
candid
sanofi
pasteur
cydtdv
requir
immun
six
month
interv
recent
approv
use
year
age
live
endem
area
overal
vaccin
offer
around
protect
dengu
diseas
variabl
efficaci
serostatu
age
vaccine
infect
serotyp
sever
diseas
review
sage
pdvac
consid
issu
trial
second
gener
vaccin
whether
would
need
compar
studi
exist
vaccin
note
circumst
randomis
placebo
control
studi
may
justifi
even
efficaci
vaccin
exist
depend
number
factor
relat
plan
initi
process
trial
design
consider
second
gener
dengu
vaccin
path
licensur
ga
caus
substanti
diseas
burden
approxim
million
peopl
suffer
seriou
ga
diseas
million
new
case
year
death
annual
greatest
mortal
burden
due
rheumat
heart
diseas
invas
ga
diseas
matern
sepsi
also
contribut
significantli
previou
human
challeng
studi
well
vaccin
trial
suggest
biolog
feasibl
develop
vaccin
howev
vaccin
develop
imped
safeti
concern
regard
potenti
induct
gasmedi
autoimmun
diseas
acut
rheumat
fever
arf
acut
poststreptococc
glomerulonephr
apgn
although
number
recombin
multival
vaccin
candid
develop
struggl
secur
invest
beyond
earli
stage
clinic
studi
pdvac
recommend
two
separ
invest
case
develop
ga
commun
target
invest
public
sector
base
prevent
sever
outcom
resourc
poor
set
southern
africa
part
asia
certain
high
risk
commun
includ
australasia
ii
privat
sector
incorpor
high
incom
countri
hic
market
prevent
pharyng
due
ga
lmic
market
prevent
cardiac
diseas
outcom
invest
case
assist
ga
scientif
commun
pdvac
fund
agenc
determin
optim
product
develop
strategi
ga
vaccin
herp
simplex
viru
type
extrem
common
sexual
transmit
infect
sti
affect
million
peopl
age
year
global
lifelong
recurr
genit
lesion
hsv
type
infect
major
world
popul
typic
caus
oral
lesion
also
increasingli
import
caus
genit
infect
control
infect
particular
concern
lmic
increas
acquisit
transmiss
hiv
infect
previou
develop
effort
prophylact
hsv
vaccin
show
efficaci
demonstr
efficaci
suggest
vaccin
class
virus
biolog
feasibl
current
therapeut
vaccin
candid
advanc
prophylact
indic
one
candid
demonstr
reduct
viral
shed
pdvac
note
develop
robust
invest
case
includ
updat
morbid
mortal
data
global
burden
neonat
herp
hsvassoci
hiv
infect
may
help
catalys
vaccin
develop
updat
global
estim
preval
incid
infect
recent
publish
first
global
region
estim
includ
preval
incid
age
year
genit
age
year
neonat
herp
estim
underway
pdvac
also
recommend
effort
gener
better
primari
data
neonat
herp
lmic
particular
includ
hsv
infect
minim
invas
autopsi
assess
undertaken
child
health
mortal
prevent
surveil
network
champ
pdvac
note
major
incent
develop
hsv
vaccin
addit
public
health
burden
directli
attribut
virus
potenti
reduc
hiv
infect
rate
order
better
understand
potenti
impact
prophylact
therapeut
vaccin
may
hiv
transmiss
diseas
commiss
updat
systemat
review
effect
infect
subsequ
hiv
incid
addit
other
hsv
commun
collabor
develop
sti
vaccin
roadmap
recent
updat
includ
issu
element
requir
formul
hsv
vaccin
invest
case
order
incentiv
fund
pharmaceut
compani
engag
develop
vaccin
object
vaccin
prepared
blueprint
formul
strateg
roadmap
implement
plan
enabl
circumvent
obstacl
typic
imped
preemptiv
vaccin
develop
prior
onset
public
health
emerg
facilit
time
effect
r
respons
inevit
futur
emerg
occur
emerg
pathogen
area
present
pdvac
mer
nipah
chikungunya
virus
assess
part
blueprint
discuss
pdvac
review
vaccinerel
element
pathogen
prior
blueprint
review
whilst
ensur
complementar
guidanc
develop
relat
drug
diagnost
non
productdevelop
relat
research
part
holist
r
focu
emerg
pathogen
first
ebola
vaccin
target
product
profil
finalis
decemb
draft
ppc
consult
meet
initi
work
roadmap
toward
mer
vaccin
emerg
respons
occur
decemb
pathogen
review
focu
vaccin
like
enter
clinic
proofofconcept
studi
within
next
three
year
clostridium
difficil
recent
publish
phase
iii
trial
helicobact
pylori
enteroviru
candid
perform
china
also
discuss
addit
evalu
new
vaccin
pdvac
role
first
gener
vaccin
licens
develop
improv
second
gener
product
need
ongo
unmet
public
health
need
lmic
keep
remit
product
develop
effort
ongo
second
gener
pneumococc
vaccin
well
rotaviru
like
discuss
case
dengu
malaria
vaccin
pdvac
note
vaccin
develop
diseas
enter
critic
stage
wherebi
guidanc
trial
design
endpoint
relat
second
gener
vaccin
need
recommend
initi
develop
guidanc
gener
pdvac
note
mani
import
platform
technolog
novel
viral
vector
innov
antigen
design
broadli
neutralis
antibodi
approach
often
emerg
hiv
malaria
vaccin
r
therefor
imper
inform
potenti
crosscut
clinic
portfolio
commun
field
begun
collat
summari
inform
global
vaccin
portfolio
across
sever
pathogen
field
includ
hiv
tb
malaria
respiratori
enter
pathogen
avail
http
whointimmun
researchvaccin
pipelin
tracker
spreadsheeten
pdvac
review
process
offer
mechan
deep
dive
product
develop
issu
opportun
across
rang
pathogen
solicit
guidanc
expert
vaccin
field
sever
excit
develop
last
year
vaccin
commun
look
forward
progress
diseas
area
discuss
next
meet
pdvac
plan
june
